We can’t show the full text here under this license. Use the link below to read it at the source.
A single-cell multi-omics framework identifies immune cell drivers of migraine and repurposable therapeutics
Single-cell analysis identifies immune cells linked to migraine and potential treatments
AI simplified
Abstract
Four genes were identified as high-priority targets for migraine treatment, with a posterior probability greater than 0.90 of sharing causal variants with migraine risk.
- Causal effects of 9,117 unique genetic variants on migraine were assessed across 14 immune cell types.
- Differential expression patterns of the identified genes were observed in various cell types and migraine-related conditions.
- Safety assessments indicated a low risk of off-target effects in multiple body systems for the identified targets.
- Three repurposable drug candidates were identified, including one approved drug and two investigational drugs, with potential therapeutic applications for migraine.
AI simplified
Key numbers
1.001
Increased Migraine Risk per Gene Expression Unit (PRDM11)
Odds ratio for PRDM11 expression in NK cells.
1.002
Increased Migraine Risk per Gene Expression Unit (C6orf25)
Odds ratio for C6orf25 expression in B IN cells.
0.998
Protective Effect per Gene Expression Unit (VIM)
Odds ratio for VIM expression in CD8 ET cells.